[Press Release]PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma_Business wire
2018-10-02
[Press Release]PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma_Business wire
대전광역시 유성구 유성대로1689번길 70, 2동 2층
(전민동,KT 대덕 2연구센타)
2F, Research Building 2, 70,
Yuseong-daero 1689 beon-gil,
Yuseong-gu, Daejeon, 34047, Republic of Korea
HQ +82-42-863-2017
R&D Center +82-42-861-2017
Investor Relations +70-4294-6097
FAX +82-42-863-2080
COPYRIGHT BY PharmAbcine Inc.
ALL RIGHTS RESERVED.
" PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma "